Acurx Pharmaceuticals, Inc. (ACXP) intrinsic value & 10-year financials
Acurx Pharmaceuticals, Inc. (ACXP) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.10
- Market cap
- $1.6M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -251.6%
- Free cash flow (FY2025)
- —
ACXP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$8.0M | -$5.32 | — | — | -270.8% |
| FY2024 | — | -$14.1M | -$0.87 | — | — | -534.0% |
| FY2023 | — | -$14.6M | -$1.15 | — | — | -243.3% |
| FY2022 | — | -$12.1M | -$1.12 | — | — | -122.6% |
| FY2021 | — | -$12.7M | -$1.49 | — | — | -168.7% |
| FY2020 | — | -$4.6M | -$0.74 | — | — | -170.3% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Acurx Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Acurx Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -22.7% ROIC.
Acurx Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Acurx Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.